DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock

The DAPT SHOCK AMI trial is the first major study to evaluate antiplatelet therapy specifically in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI). It compares initial treatment strategies using cangrelor versus crushed ticagrelor. Early and potent platelet inhibition is critical for restoring microvascular reperfusion in this high-risk population. Previous randomized trials have excluded these patients, leaving a gap in evidence for optimal antiplatelet management in AMI-CS.

In this interview, Drs. Dipti Itchhaporia and Zuzana Motovska discuss "DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock".

Subscribe to ACCEL